CLINICAL_TRIALS
trial_result
· 2025-01-16
Clinical Trial Update: A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC [Phase 2]
Summary
A Phase 2 trial of seladelpar for primary sclerosing cholangitis was terminated; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Gilead Sciences | Conditions: Primary Sclerosing Cholangitis | Phase 2 | Status: TERMINATED | Results posted: 2025-01-16